CD163 and pancreatic neoplasm: Patients with pancreatic cancer with high expression of both CD163 and MARCO had the shortest DFS (3.0 months vs 10.0 months vs 19.0 months, P = 0.0146 and P = 0.0004, receptively) and OS (7.5 months vs 22.0 months vs 34.5 months, P = 0.0004 and P = 0.0004, respectively) among patients with high expression of only CD163 or MARCO and patients with low expression of both CD163 and MARCO (Figures 7E, F).